We have experienced a number of cases of AML1/ETO þ acute myelogenous leukemia that showed remission based on bone marrow (BM) morphological criteria, but that revealed clonal abnormalities in most cells by fluorescence in situ hybridization (FISH). Interestingly, most of these cases had AML with AML1/ETO rearrangement. The malignant cells were differentiated and considered mature cells after granulocyte-colony stimulating factor (G-CSF) treatment. To clarify the possible mechanisms underlying this phenomenon, we investigated the expression levels of G-CSFR in AML cells with AML1/ETO rearrangement by flow cytometry and real-time polymerase chain reaction (PCR). The number of AML1/ETO þ cells expressing G-CSFR at baseline was significantly higher than that of AML1/ETO À AML cells (2673 vs 522). In addition, the G-CSFR gene was more highly expressed in AML1/ETO þ cells than in AML1/ETO À cells by real-time PCR. This study reveals that cases showing remission after treatment with G-CSF mostly had leukemia with AML1/ETO rearrangement. This finding might be explained by the higher expression of G-CSF receptor in AML1/ETO þ cells than in AML1/ETO À cells. We recommend that remission should be confirmed by FISH, because malignant clones can be differentiated and masked in morphological examination or chromosome test, especially for AML with AML1/ETO rearrangement.
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Introduction
Acute myeloid leukemia (AML) results in an accumulation of blasts with variable degrees of myeloid differentiation. Moreover, the proliferation, differentiation, and survival of hematopoietic cells are regulated by hematopoietic cytokines, 1 and granulocyte-colony stimulating factor (G-CSF) stimulates both the proliferation and differentiation of neutrophil precursor cells. G-CSF also stimulates a variety of responses in mature neutrophils, including prolonged survival, phagocytosis and superoxide production.
2-4 G-CSF binds to its cell surface receptor (G-CSFR) to form a homodimeric receptor complex. 1, 5 Moreover, the membrane-proximal region of G-CSFR has been shown to be essential for the transmission of growth signals via JAK2 activation, STAT3 and STAT5 phosphorylation and MAP kinase phosphorylation. 2, 6, 7 The therapeutic use of G-CSF for acute leukemia remains controversial due to the fear that it may stimulate the proliferation and differentiation of malignant cells in myeloid leukemia in addition to normal myeloid precursors. Moreover, several studies have been performed on the spontaneous remission of AML after infection or treatment with G-CSF alone, that is, without chemotherapy. [8] [9] [10] However, a literature review later revealed that many of these cases showed subsequent relapse of the leukemia after temporary remission and finally died. 8, 11 In addition, we experienced a small number of cases who showed remission based on bone marrow (BM) morphological criteria, but who revealed clonal abnormalities in most cells after G-CSF administration. Interestingly, most of these cases had AML with AML1/ETO rearrangement. To identify the mechanisms underlying this phenomenon, we investigated the expression levels of G-CSFR in AML cells with AML1/ETO rearrangement.
Materials and methods

Patients
Two hundred and forty-four patients initially diagnosed with AML and hospitalized at Seoul National University Hospital between 1998 and 2003, were subjected to a conventional cytogenetic study and AML1/ETO fluorescence in situ hybridization (FISH), PML/RARA FISH and MLL FISH were performed as previously described.
12 FISH probes were manufactured by Vysis Inc. (Downers Grove, IL, USA). Of the 244 patients, 96 (28.3%) were positive for a genetic change at initial diagnosis by FISH; these patients were subjected to FISH and to a conventional chromosome study during a follow-up BM examination. At these follow-up BM examinations, 80 of the 96 patients (83%) had reached complete remission.
Six of these 96 cases showed discrepant BM examination and FISH test results. They all showed morphologically complete remission, displaying fewer than 5% myeloblasts or much reduced blast counts by BM examination but positive clonal changes in more than 50% of cells by FISH. All of these cases had received G-CSF for an alleged or a suspected infection and absolute neutropenia (o500/ml). Of note, five cases had AML with AML1/ETO rearrangement and one case had AML with trisomy 8. Summaries of these six cases and of the discrepancies between BM examination and FISH test results are presented in Table 1 .
Cell lines and samples of BM cells
The AML1/ETO þ Kasumi-1 and AML1/ETO À CTV-1 cell lines were obtained from the Korean Cell Line Bank (KCLB, Seoul). Kasumi-1 and CTV-1 cells were cultured in RPMI-1640 supplemented with 10% FBS, 2 mM L-glutamine, 100 mg/ml streptomycin sulfate, and 100 U/ml of penicillin G for 7 days, and were maintained in a 371C, 5% CO 2 , fully humidified incubator.
BM aspirates were analyzed from 13 patients with AML1/ ETO þ AML (nine males, four females, mean age: 39 years ranging from 21 to 56 years) and 20 patients with AML without recurrent genetic abnormalities (14 males, six females, mean age: 41 years ranging from 18 to 64 years). Of the 13 patients with AML1/ETO þ AML, 12 were M2 and one was M1 according to FAB classification. Of the 20 patients without recurrent genetic abnormalities, 13 patients were M2, four M1, two M4 and one was M5. Mononuclear cells were isolated by Ficoll Hypaque (density 1.077 g/cm 3 ) density gradient centrifugation.
Flow cytometry analysis for G-CSFR
Immunofluorescence studies were performed using a commercially available anti-G-CSFr (Serotec, Oxford, UK) according to the manufacturer's instructions. Fluorescence was analyzed by flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA, USA) using CELLQuest software (Becton Dickinson). The proportion of positive events in the defined gates (blast population) were calculated, and the mean number of bound phycoerythrin (PE) molecules per cell was calculated using the QuantiBrite and QuantiQuest programs (Becton Dickinson). 13 Real-time PCR RNA extraction and reverse transcription. Changes in AML1/ETO gene expression were investigated by real-time PCR in the AML1/ETO þ Kasumi-1 cell line, the AML1/ETO À CTV-1 cell line, and in BM samples. RNA was extracted using TRIzol Reagent (Life Technologies, Gaithersburg, MD, USA), according to the manufacturer's instructions. Reverse transcription was performed using a commercial kit using Moloney murine leukemia virus reverse transcriptase (SuperScript II Reverse Transcriptase, Invitrogen Corporation, Carlsbad, CA, USA) according to the manufacturer's protocol; reaction mixtures were incubated at 251C for 10 min, 421C for 50 min and finally at 701C for 15 min.
Real-time quantitative PCR analysis for G-CSFR. Realtime quantitative PCR was performed in triplicate in 384-well plates; each 20 ml reaction mix consisted of 10 ml of Universal TaqMan Probe Master Mix (Applied Biosystems), and 0.8 ml of 10 pM forward and reverse primer sets. Amplification was performed at 501C for 2 min and 951C for 10 min followed by 40 cycles of 951C for 30 s, 601C for 30 s and 721C for 30 s. TaqMan analysis was used for CSF3R (Hs00167918_m1) and GAPDH (Hs99999905_m1) gene expression using the primers and conditions designated by assays on demand, gene expression products (Applied Biosystems, Foster City, CA, USA). Each 384-well real-time quantitative PCR plate included serial dilutions (1, 1/2, 1/4, 1/8 and 1/16) of cDNA, which were used to generate relative standard curves for CSF3R and GAPDH. We then converted real-time PCR cycle numbers to gene amounts (ng) using the equation. Real-time PCR was performed on an Applied Biosystems Prism 7900 Sequence Detection System. Data were analyzed using ABI Prism 7700 SDS software (version 1.0). The expressions of specific genes were normalized vs GAPDH mRNA expression.
Statistical analysis
Data were analyzed using the Student's t-test or the MannWhitney U-test using SPSS software (SPSS Inc., Chicago, IL, USA). P-values of less than 0.05 were considered statistically significant. 
Results
Quantitation of G-CSFR in the
Real time PCR for G-CSFR gene expression
The AML1/ETO þ Kasumi-1 cell line expressed the G-CSFR gene, whereas the AML1/ETO À CTV-1 cell line did not. In patient's bone marrow specimens, G-CSFR gene expression was higher in AML patients with AML1/ETO rearrangement than in those without (Figure 2 , mean relative expression 1.37 vs 0.45; P ¼ 0.019).
Discussion
G-CSF is commonly used to treat of neutropenia, which often occurs during chemotherapy, and G-CSF production can be increased endogenously in response to infection. Based on a review of previous leukemia cases that entered remission after treatment with G-CSF, it became apparent that true remission was probably never achieved with G-CSF alone, as seven of 17 cases that were believed to have entered remission subsequently relapsed. 8 A few blast cells observed in the BM at the time of hematological remission were leukemic clones, and the remissions induced by G-CSF were almost always found to be transient. 8, 11, 14 Moreover, morphologically complete remission was classified based on BM examination, because malignant cells were differentiated they were considered to be mature myeloid cells, and thus satisfied the morphological criteria for complete remission. In addition, all previously reported cases who reached complete remission after G-CSF treatment showed negative chromosome test, however, FISH was not performed. [9] [10] [11] 15 One report of an in vitro effect of G-CSF on AML with t(6;9) found that leukemic cells differentiated to neutrophils. 16 The authors compared the effects of four kinds of cytokines including G-CSF, GM-CSF, IL-3 and stem cell factor and found that IL-3, G-CSF and GM-CSF had a proliferative effect on leukemia blasts. For this reason, they strongly advised that G-CSF should be used cautiously for the treatment of AML. Another report showed that an AML patient with t(6;9) reached complete remission after treatment with G-CSF. 15 In two other reports, the leukemic cells of AML patients were found to differentiate to neutrophils after G-CSF administration, but no cytogenetic study was performed. 17, 18 Of the 244 AML patients treated at our institution during the past 6 years, we recorded six cases who showed morphological complete remission or a reduced blast count upon BM examination, but who revealed clonal changes in most cells by FISH. For example, in case 1, the number of myeloblasts in peripheral blood rapidly reduced to 0% following her fever and leukocytes observed in a peripheral blood smear were mostly segmented or band neutrophils. However, 95.5% of these cells were AML1/ETO rearrangement-positive according to FISH test in same peripheral blood specimens. To determine the cause of these discrepancies, Wright staining was performed on slides used for FISH staining. The AML1/ETO þ cells by FISH testing were identified as neutrophils, and were presumed to have differentiated from malignant leukemic cells, moreover, auer rods were observed in some neutrophils (Figure 3) .
These cells included malignant clones with proliferative activity, as four of the six patients in the present study also had abnormal chromosome tests. However, one patient (case 5) had a normal karyotype according to a chromosome test; thus indicating that a lack of cytogenetic changes in a chromosome test cannot be considered as evidence of remission. Interestingly, five of the six cases were AML with AML1/ETO rearrangement, and most of the patients involved eventually relapsed and died (Table 1 ). Lee et al. 19 also reported that adult patients with t(8;21) AML did not have a better treatment outcome than those without t(8;21). Shimizu et al.
2 demonstrated that AML1/ETO fusion protein upregulates CCAAT/enhancer binding protein epsilon, and thus increases G-CSF receptor expression in leukemic cells. In addition, it was suggested that AML1/ETO fusion protein stimulates the transcription of an antiapoptotic factor, the BCL-2 gene, which explains the existence of residual leukemic clones. 20 The AML1/ETO gene downregulates C/EBPa, which causes the differentiation of granulocytes and results in leukemia. 21 Using a leukemic cell line culture and transgenic mice, Ferrara et al. 10 showed that adding G-CSF to cell culture medium caused AML1/ETO þ cells to differentiate into mature neutrophils. Moreover, in an animal experiment, expression of the AML1/ETO gene was found to result in abnormal maturation and the proliferation of progenitor cells in transgenic mice. 22 In the present study, G-CSFR was found to be expressed in the majority of the AML1/ETO þ Kasumi-1 cell line, but was not in the AML1/ETO À CTV-1 cell line. After G-CSF administration, quantities of G-CSFR (expressed as mean PE molecules) in Kasumi-1 cells reduced from 2673 to 1953 per cell, which may have been due to the blocking of the anti-G-CSFr binding site in G-CSFR 13 or to reduced G-CSFR production. In addition, the mean quantities of G-CSFR in AML1/ETO þ AML cells were found to be significantly higher than in AML1/ETO À AML cells. Moreover, real-time PCR showed that the AML1/ETO þ Kasumi-1 cell line expresses the G-CSFR gene, whereas the AML1/ETO À CTV-1 cell line did not. Similarly, G-CSFR gene expression was found to be higher in the BM specimens of AML patients with the AML1/ETO rearrangement than in those without (Figure 2) .
Two recent studies also reported that higher levels of G-CSFR are expressed in M2 and M3 AML than in other AML types. 1, 23 These results may explain why cases that showed remission after G-CSF treatment in our study predominantly had AML with AML1/ETO rearrangement. AML1/ETO þ leukemic cells with higher G-CSFR expression would be expected to be more affected by G-CSF, that is, the differentiation or proliferation of leukemic blasts. Although patients with the AML1/ETO rearrangement are known to have a better prognosis than those with normal karyotypes, they show a clinically poorer prognosis because G-CSF used for treatment stimulates the proliferation and differentiation of AML cells and leads to the impression of remission according to morphological criteria. Most of the cases in the present study had (or were suspected to have) infections and were administered antibiotics. The amounts of G-CSF administered in the six cases ranged from 30 to 450 mg/sc. Moreover, G-CSF which were administered and endogenously produced by infection seems to bring about a synergistic effect. In addition, we observed that neutrophils that had differentiated from leukemic cells with the AML1/ETO rearrangement have a unique shape, that is, a dumbbell-shaped nucleus with thick ends and cytosol having dark granules, and some of these cells had auer rods in the cytosol.
In conclusion, our study reveals that cases that show remission after treatment with G-CSF predominantly have leukemia with AML1/ETO rearrangement. This finding might be explained by the higher expression of G-CSF receptor in AML1/ETO þ cells than in AML1/ETO À cells. Thus, we recommend that complete remission should be confirmed by FISH, because malignant clones can be differentiated by G-CSF, then masked in morphological examination or chromosome test, especially for AML with AML1/ETO rearrangement. Therapeutic use of G-CSF could conceal residual malignant cells
